SEC Form 4 · accession 0001104659-16-097471
CATABASIS PHARMACEUTICALS INC · CATB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Deirdre A. Cunnane
Officer — SVP, General Counsel
Period of report
Feb 11, 2016
Accepted (ET)
Feb 16, 2016 · 6:18 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001454789
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $4.57 | Feb 11, 2016 | A | 23,000 | A | — | Feb 10, 2026 | Common Stock | 23,000 | 23,000 | D |
Explanation of responses
- F1This option was granted on February 11, 2016 and is scheduled to vest over four years, with 25% of the shares vesting on the first anniversary of February 11, 2016 and the remainder vesting over the ensuing three years at a rate of 2.0833% per month.